129 related articles for article (PubMed ID: 12739061)
1. Pharmacokinetics and tissue distribution of cryptophycin 52 (C-52) epoxide and cryptophycin 55 (C-55) chlorohydrin in mice with subcutaneous tumors.
Boinpally RR; Polin L; Zhou SL; Jasti BR; Wiegand RA; White K; Kushner J; Horwitz JP; Corbett TH; Parchment RE
Cancer Chemother Pharmacol; 2003 Jul; 52(1):25-33. PubMed ID: 12739061
[TBL] [Abstract][Full Text] [Related]
2. Preclinical anticancer activity of cryptophycin-8.
Corbett TH; Valeriote FA; Demchik L; Polin L; Panchapor C; Pugh S; White K; Knight J; Jones J; Jones L; LoRusso P; Foster B; Wiegand RA; Lisow L; Golakoti T; Heltzel CE; Ogino J; Patterson GM; Moore RE
J Exp Ther Oncol; 1996 Mar; 1(2):95-108. PubMed ID: 9414393
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of cryptophycins: effect of infusion time and combination studies.
Menon K; Alvarez E; Forler P; Phares V; Amsrud T; Shih C; Al-Awar R; Teicher BA
Cancer Chemother Pharmacol; 2000; 46(2):142-9. PubMed ID: 10972484
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression.
Geary RS; Leeds JM; Fitchett J; Burckin T; Truong L; Spainhour C; Creek M; Levin AA
Drug Metab Dispos; 1997 Nov; 25(11):1272-81. PubMed ID: 9351904
[TBL] [Abstract][Full Text] [Related]
5. Preclinical pharmacology of the natural product anticancer agent bryostatin 1, an activator of protein kinase C.
Zhang X; Zhang R; Zhao H; Cai H; Gush KA; Kerr RG; Pettit GR; Kraft AS
Cancer Res; 1996 Feb; 56(4):802-8. PubMed ID: 8631017
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to bcl-2, after intravenous administration or continuous subcutaneous infusion to mice.
Raynaud FI; Orr RM; Goddard PM; Lacey HA; Lancashire H; Judson IR; Beck T; Bryan B; Cotter FE
J Pharmacol Exp Ther; 1997 Apr; 281(1):420-7. PubMed ID: 9103525
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic studies in mice of two new thioxanthenones (183577 and 232759) that showed preferential solid tumor activity.
Foster BJ; Wiegand RA; Pugh S; LoRusso PM; Rake J; Corbett TH
Clin Cancer Res; 1997 Nov; 3(11):2047-53. PubMed ID: 9815596
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and tissue distribution of a DNA-methyltransferase antisense (MT-AS) oligonucleotide and its catabolites in tumor-bearing nude mice.
Qian M; Chen SH; von Hofe E; Gallo JM
J Pharmacol Exp Ther; 1997 Aug; 282(2):663-70. PubMed ID: 9262328
[TBL] [Abstract][Full Text] [Related]
9. Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1.
Egorin MJ; Zuhowski EG; Rosen DM; Sentz DL; Covey JM; Eiseman JL
Cancer Chemother Pharmacol; 2001 Apr; 47(4):291-302. PubMed ID: 11345645
[TBL] [Abstract][Full Text] [Related]
10. Preclinical pharmacology of CB30900, a novel dipeptide inhibitor of thymidylate synthase, in mice.
Walton MI; Gibson W; Aherne GW; Lawrence N; Stephens TC; Smith MN; Jackman AL
J Pharmacol Exp Ther; 1996 May; 277(2):909-16. PubMed ID: 8627573
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic/pharmacodynamic study of ZD9331, a nonpolyglutamatable inhibitor of thymidylate synthase, in a murine model following two curative administration schedules.
Aherne GW; Hardcastle A; Ward E; Dobinson D; Crompton T; Valenti M; Brunton L; Jackman AL
Clin Cancer Res; 2001 Sep; 7(9):2923-30. PubMed ID: 11555611
[TBL] [Abstract][Full Text] [Related]
12. Altered distribution of copper (64Cu) in tumor-bearing mice and rats.
Apelgot S; Coppey J; Fromentin A; Guille E; Poupon MF; Roussel A
Anticancer Res; 1986; 6(2):159-64. PubMed ID: 3707051
[TBL] [Abstract][Full Text] [Related]
13. Hexamethylmelamine and pentamethylmelamine tissue distribution in M5076/73A ovarian cancer-bearing mice.
Broggini M; Rossi C; Colombo T; D'Incalci M
Cancer Treat Rep; 1982 Jan; 66(1):127-33. PubMed ID: 6796267
[TBL] [Abstract][Full Text] [Related]
14. The pharmacokinetics, bioavailability and biodistribution in mice of a rationally designed 2-nitroimidazole hypoxia probe SR-4554.
Aboagye EO; Lewis AD; Graham MA; Tracy M; Kelson AB; Ryan KJ; Workman P
Anticancer Drug Des; 1996 Apr; 11(3):231-42. PubMed ID: 8663910
[TBL] [Abstract][Full Text] [Related]
15. Comparative pharmacokinetics of KRN8602, a new morpholino anthracycline, and adriamycin in tumor-bearing mice.
Shinkai H; Takahashi H; Miyamoto K; Uchida T; Tokiwa T
Cancer Chemother Pharmacol; 1996; 38(5):417-24. PubMed ID: 8765434
[TBL] [Abstract][Full Text] [Related]
16. Binding of the epoxide cryptophycin analog, LY355703 to albumin and its effect on in vitro antiproliferative activity.
Schultz RM; Shih C; Wood PG; Harrison SD; Ehlhardt WJ
Oncol Rep; 1998; 5(5):1089-94. PubMed ID: 9683814
[TBL] [Abstract][Full Text] [Related]
17. Cryptophycin 52 and cryptophycin 55 in sequential and simultaneous combination treatment regimens in human tumor xenografts.
Teicher BA; Forler P; Menon K; Phares V; Amsrud T; Shih C
In Vivo; 2000; 14(4):471-80. PubMed ID: 10945160
[TBL] [Abstract][Full Text] [Related]
18. Pharmokinetics of 2'-deoxycoformycin in normal and L1210 leukemic mice.
McConnell WR; Furner RL; Hill DL
Drug Metab Dispos; 1979; 7(1):11-3. PubMed ID: 35319
[TBL] [Abstract][Full Text] [Related]
19. Disposition of the monoclonal antibody-vinca alkaloid conjugate KS1/4-DAVLB (LY256787) and free 4-desacetylvinblastine in tumor-bearing nude mice.
Spearman ME; Goodwin RM; Apelgren LD; Bumol TF
J Pharmacol Exp Ther; 1987 May; 241(2):695-703. PubMed ID: 3494841
[TBL] [Abstract][Full Text] [Related]
20. Three new cryptophycins from Nostoc sp. GSV 224.
Subbaraju GV; Golakoti T; Patterson GM; Moore RE
J Nat Prod; 1997 Mar; 60(3):302-5. PubMed ID: 9090872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
